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Although antischistosomal properties of peroxides were studied in recent years, systematic structure-
activity relationships have not been conducted. We evaluated the antischistosomal potential of 64 
peroxides belonging to bridged 1,2,4,5-tetraoxanes, alphaperoxides and β,δ-triketones. 
Thirty-nine compounds presented IC50 values < 15 µM on newly transformed schistosomula. Active drugs 
featured phenyl-, adamantane- or alkyl residues at the methylene bridge. Lower susceptibility was 
documented on adult schistosomes, with most hit compounds being tricyclic monoperoxides (IC50: 7.7-
13.4 µM). A bridged 1,2,4,5-tetraoxane characterized by an adamantane residue showed the highest 
activity (IC50: 0.3 µM) on adult Schistosoma mansoni. Studies with hemin and heme supplemented 
medium indicated that antischistosomal activation of peroxides is not necessarily triggered by iron 
porphyrins. Two compounds (tricyclic monoperoxide; bridged 1,2,4,5-tetraoxane) revealed high worm 
burden reductions in the chronic (WBR: 75.4-82.8 %) but only moderate activity in the juvenile 
(WBR:18.9-43.1%) S. mansoni mouse model. Our results might serve as starting point for the preparation 










Schistosomiasis remains one of the most prevalent parasitic diseases, being endemic in 76 countries 
worldwide with approximately 780 million people at risk of infection.1 The infection is caused by 
trematodes of the genus Schistosoma, among which Schistosoma mansoni, S. haematobium and S. 
japonicum represent the most important pathogenic species for humans. During chronic infections 
worms persist in the liver and hepatic portal system or urinary tract system, depending on the species. 
Mature schistosomes start laying eggs within their habitation, which often get trapped in the tissues 
resulting in inflammatory and obstructive diseases of affected organs.2 In order to cure subtle morbidity 
and prevent the development of severe late stage morbidity at risk populations are periodically treated 
with praziquantel, the drug of choice for treating schistosomiasis.3 Following the discovery of the 
antischistosomal properties of the artemisinins, in recent years various compounds characterized by a 
peroxidic scaffold were studied in detail for their antischistosomal activity. The overarching goal of these 
studies was to identify a drug with high activity against both, juvenile and adult schistosomes. In contrast 
to praziquantel, the artemisinins revealed high activities against juvenile schistosomes but low to 
moderate activities on the adult worms in S. mansoni infected mice.4,5 Studies with fully synthetic 
compounds including ozonides6,7, trioxaquines8 and dioxolanes9 were undertaken. In more detail, 
amongst the aryl-ozonides OZ418 was identified as the most promising lead candidate possessing high 
activity on both juvenile and adult schistosome infections in mice.6 The trioxaquine lead candidate 
PA1259, a hybrid drug containing an aminoquinoline so as trioxane pharmacophore, was characterized 
by moderate in vivo activity on juvenile and adult S. mansoni in mice.8,10 In another study a praziquantel-
ozonide hybrid was designed, which however failed to demonstrate in vivo activity.11,12 Finally, the 
relationship between the peroxidic scaffold and antischistosomal activity was underscored testing a 
series of alkoxydioxolanes in vitro and in vivo.9 
However, despite the evaluation of several peroxidic compound classes for their effect on schistosomes, 
only little is known on the relationship between the peroxidic structures and antischistosomal activity. 
Therefore we were interested in elucidating the antischistosomal potential of three practically new 
peroxide classes, namely bridged 1,2,4,5-tetraoxanes, tricyclic monoperoxides and alphaperoxides in 
vitro and in vivo against S. mansoni for the first time. Bridged 1,2,4,5-tetraoxanes present with a 
methylene bridge within the pharmacophore which distinguishes them from described 1,2,4,5-
tetraoxanes with known trematocidal activity.13 The preparation of these peroxide classes has been 
developed recently and their syntheses imply high yields using inexpensive and accessible reagents.14-17 A 
library with small drug like molecules showing high structural variability was synthesized for each class of 
compounds and tested in vitro on Newly Transformed Schistosomula (NTS) and adult S. mansoni. The 
antischistosomal activity of selected compounds was additionally studied in the presence of hemin and 
heme, as possible activators. Compounds revealing high activity in vitro were next tested on toxicity and 
further characterized in vivo using a patent S. mansoni mouse model. Finally, compounds being active in 
the chronic infection model progressed into the juvenile infection model to characterize the full 
spectrum of activity of these peroxides. 
RESULTS 
In vitro screening on NTS. In a first step the four compound libraries consisting of 27 tetraoxanes, 19 
tricyclic monoperoxides, 17 alphaperoxides and one 2-(1-adamantylperoxy)-tetrahydrofuran (Table 1) 
were tested on S. mansoni NTS. Our workflow is presented in Figure 1. Results are summarized in Table 
2. Thirty-nine compounds (24 tetraoxanes, 9 tricyclic monoperoxides and 6 alphaperoxides) showed high 
activities (as defined by half-maximal inhibitory concentrations (IC50’s) < 15 μM) on NTS. In more detail, 
24 tetraoxanes (89%) revealed IC50 values ranging from 0.1- 13.9 μM. Six of these had IC50 values even 
lower than 1 μM with compounds 18 (IC50: 0.1 μM) and 19 (IC50: 0.2 μM) displaying the highest activity. 
Hence the most active tetraoxanes showed at least 10-fold increased activity when compared to 
reference drug praziquantel (IC50: 2.2 μM) and 25-fold increase in activity when compared to artesunate 
(IC50: 5.0 μM) on the schistosomular stage. The remaining three of the 27 tetraoxanes tested 
(compounds 42-44) showed low to moderate activity (IC50’s: 15.3 - 58.1 μM). Compound 45 was the most 
active compound in the class of tricyclic monoperoxides (IC50: 1.7 μM). Eight tricyclic monoperoxides had 
IC50 values ranging from 3.5 to 14.4 μM. The remaining compounds showed low to moderate activity 
(IC50’s: 15.6-213.2 μM compounds 54-60) or lacked activity (61-63) (motility decreased less than 50 % at 
the highest concentration tested). Of the 17 alphaperoxides tested six compounds (6,7,9,13-14,17) were 
highly active (IC50’s: 3.9 -14.6 μM), eight molecules showed low to moderate activities (IC50’s 15.1- 293.0 
μM) and three compounds lacked activity (compound 1,2,5). Finally the tested 2-(1-adamantylperoxy)-
tetrahydrofuran (compound 64) lacked activity on the schistosomular stage. 
In vitro screening on adult schistosomes. Thirty-nine compounds progressed into the adult S. mansoni 
screens (Table 2). Of these, six compounds (1 tetraoxane, 4 tricyclic monoperoxides and 1 alphaperoxide) 
showed high activity (defined as IC50’s < 15 μM) against adult S. mansoni. The highest activity was 
observed with tetraoxane 18 characterized by an IC50 of 0.3 μM, revealing comparable in vitro activity as 
the reference drug praziquantel (IC50: 0.08 μM). The two tricyclic monoperoxides (51 and 45) presented 
IC50 values of 7.7 and 8.7 μM, respectively. Compounds 12 (alphaperoxide), 49 and 53 (tricyclic 
monoperoxides) revealed similar IC50 values of 14.7, 12.2 and 11.7 μM respectively.  
Twenty-two compounds (16 tetraoxanes, 2 tricyclic monoperoxides and 4 alphaperoxides) showed a low 
to moderate activity (IC50’s: 18.8- 132.4 μM). Finally, of the 39 compounds tested 11 revealed no 
decrease of motility of more than 50% on adult S. mansoni at the highest concentration tested. 
All compounds which revealed a high antischistosomal potential on NTS (IC50 < 5.0 μM) but only low, 
moderate or no activity against adult schistosomes (12 tetraoxanes, 2 tricyclic monoperoxide and 1 
alphaperoxide) were retested in the presence of Fe (III)-hemin. In addition, four of these compounds 
were also studied in a Fe(II) –heme supplemented media.  
Selected compounds of alphaperoxides (11) and tricyclic monoperoxides (46) did not show a great 
difference in their IC50 values when incubated with (46: 92.2 µM and 11: 17.9 µM) or without (46: >123 
µM and 11: 19.3 µM) hemin. Similar patterns were also observed for the thirteen tested tetraoxanes. 
The majority (9 compounds 19,20, 22-25, 27, 29-30) showed comparable antischistosomal activity with 
or without hemin or slightly decreased activity (21, 26, 28 and 31). A considerable increase of activity 
was detected for one of the selected tricyclic monoperoxide, compound 47, lacking activity (>103 µM) 
without and showing an IC50 value of 14.4 µM with additional hemin. Finally, in the presence of a Fe(II) –
heme supplemented media three compounds still lacked activity (30, 46, 47) and only one showed a 
slight increase in activity (29; IC 50:33.6 µM). 
Determination of cytotoxicity. The eight compounds displaying high activity against adult S. mansoni in 
vitro were first tested on L6-cells for their cytotoxic potential. Artesunate and praziquantel were used as 
reference drugs, data are summarized in Table 3. The two tricyclic monoperoxides (47, 49) and 
praziquantel showed no cytotoxic potential at the highest concentration tested (30 µg/ml). Lowest 
cytotoxic potential with IC50 values of 94.4 μM and 58.3 µM were observed for the alphaperoxide 12 and 
the tricyclic monoperoxide 53, respectively. The tricyclic monoperoxides, 45 and 51, revealed similar 
moderately cytotoxic IC50 values from 8.2 µM (46) to 10.3 μM (52). Furthermore both selected 
tetraoxanes 18 (1.7 μM) and 25 (2.2 μM) showed similar cytotoxic effects on L6-cells as observed for 
artesunate (IC50: 1.5 μM). Selectivity indices ranged from 0.2 for compound 25 to 7.6 for compound 49 
(Table 3). Lead candidates (18, 53) (based on the in vivo activity results, see below) and artesunate were 
further investigated on two different human cell lines, namely HeLa and MRC-5. All compounds showed 
twofold higher effects on the cancer cell line (HeLa) than on the normal cell line (MRC-5). The lowest 
cytotoxicity was determined for the tricyclic alphaperoxide 53 (IC50 of 6.0 µM on HeLa and 12.4 µM on 
MRC-5) followed by artesunate (IC50 of 3.2 µM on HeLa and 6.8 µM on MRC-5). Tetraoxane 18 showed 
cytotoxic potential on both cell lines (IC50 of 0.4 µM on HeLa and 1.2 µM on MRC-5).  
In vivo efficacy on adult S. mansoni infection. Based on their in vitro activity against adult schistosomes 
(IC50<15 µM) two tetraoxanes (18, 25), five tricyclic monoperoxides (45, 47, 49, 51 and 53), and one 
alphaperoxide (12) were tested in mice harboring an adult S. mansoni infection (Table 4). The 
alphaperoxide 12 and tricyclic monoperoxide 47 lacked in vivo activity. Treatment with three of the 
tricyclic monoperoxides and one of the tetraoxanes resulted in low total worm burden reductions (WBR) 
ranging from 4.7 – 31.3 % (compound 25: 5.0 %, compound 45: 31.3%, compound 49: 4.7% and 
compound 51: 6.5%).Good antischistosomal in vivo activity was observed with tetraoxane 18 and 
tricyclic monoperoxide 53. Compound 18 achieved a total and female WBR of 75.4 % (p=0.03) and 77.8% 
(p=0.03), respectively. For the tricyclic monoperoxide 53 significant total and female WBR’s of 82.8% 
(p=0.02) and 82.9 % (p=0.01) respectively were determined. 
In vivo efficacy studies on juvenile S.mansoni infection. Compounds 18 and 53 were tested against 
juvenile S. mansoni in vivo. The tetraoxane showed moderate total and female WBR’s of 43.1% and 50%, 
respectively. Low WBR’s were observed with the tricyclic monoperoxide with 18.9% total and 27.3% 
female WBR’s. 
DISCUSSION AND CONCLUSION 
In recent years peroxides have played a prominent role in antischistosomal drug discovery and 
development. Various studies have been conducted ranging from pre-clinical in vitro and in vivo studies 
as well as clinical trials.4,8 Nonetheless to date our knowledge is still limited with regard to the structural 
requirements these molecules need in order to elicit antischistosomal activity. Therefore in the present 
work three different peroxide classes were screened for their antischistosomal potential.  
First, compounds were studied for activity against NTS (Figure 1). Compounds with an activity < 15 µM 
against NTS were classified as active and progressed further. Abdulla and colleagues recently described a 
similar screening workflow, however using a 15 fold lower cut-off of 1 µM to obtain an acceptable hit 
rate of 10%.18 On the other hand, Mansour and Bickle noted that schistosome active drugs were best 
identified in their screen using concentrations of 10 µg/ml (i.e. 28–44 µM) in the primary NTS screen.19 
Given the excellent activity of peroxidic drugs against juvenile schistosomes4, 6, as mentioned in this work 
an IC50 value < 15 µM was selected as cut-off.  
Of 64 compounds tested, 39 (60%) showed high in vitro activity against NTS. For the class of tetraoxanes 
we detected the highest activity against the schistosomular stage (with 89% of compounds being active) 
whereas within the other two peroxide classes investigated (tricyclic monoperoxides and 
alphaperoxides) less than half of the compounds displayed activity. Most of the active tetraoxanes 
elucidated activities comparable to praziquantel on this parasite stage. Structural variation was observed 
among active compounds on schistosomula. However a tendency of structural features among highly 
active tetraoxanes and tricyclic monoperoxides could be noted. All highly active structures amongst 
these two groups presented either phenyl- (20, 22, 24-26, 30, 31 and 45), adamantane- (18, 23) or alkyl- 
(19, 21 and 28) residues at the methylene bridge.  
In contrast to results obtained on NTS with nearly all tetraoxanes being active, showed adult S. mansoni 
a lower susceptibility to these drugs with only one tetraoxane (18) revealing prominent activity. This 
compound revealed also high worm burden reductions against S. mansoni in vivo. Compound 18 displays 
an adamantane substitute at the methylene bridge. Early studies with synthetic peroxides in the 
framework of a collaborative antimalarial discovery project evaluated essential characteristics for a new 
trioxolane antimalarial drug. It was documented that necessary pharmacokinetic characteristics could be 
obtained with the spiroadamantane trioxolane pharmacophore.20 Increased lipophilicity of the 
adamantane substituted compounds resulted in higher antimalarial activity. In addition, using the same 
class of compounds as a starting point to search for a fasciocidal synthetic peroxide drug development 
candidate revealed that the spiroadamantane substructure is an essential part for fasciocidal activity.21 
Contrary to the known active spiroadamantane substructures, compound 18 does not contain a spiro-
fragment; the adamantane and tetraoxane parts are joined directly with a C-C bond.  
It is interesting to note that the tested 2-(1-adamantylperoxy)-tetrahydrofuran (64) did not expose any 
activity on the schistosomular stage which indicates that not only the presence of an adamantane part 
determines the antischistosomal activity. Therefore most probably, the key fragment which determines 
activity is the bridged tetraoxane and adamantane bears a supporting function.  
The class of tricyclic monoperoxides revealed the greatest number of hits (n=4) on adult S. mansoni in 
vitro, with compounds 45 and 51 being most active. Three of the active tricyclic monoperoxides (45, 51 
and 53) have a phenyl residue next to the peroxidic bond in common. To note, these phenyl-containing 
peroxides are unusual compounds from the chemical point of view; generally peroxides containing the 
Ar-C-O-O moiety easily decompose in accordance with heterolytic mechanism by Hock and related 
reactions.22,23  
Furthermore the substitution of the bridge of tricyclic monoperoxides seems to affect the activity as 
observed on the schistosomular stage likewise. Phenylic residues (compound 49) seem to increase the 
activity whereas a propargyl substituent results in decreased activity (as seen for compound 48). 
However, amongst the three tested compounds (45, 51 and 53) in vivo only compound 53 achieved a 
promising WBR of 82.8 %. This might be explained with a higher metabolic stability of the methylether 
substituted compound.24 
It is interesting to note that in general adult S. mansoni were less affected by the peroxides than NTS. 
This was particularly striking for the alphaperoxides and as mentioned before for the bridged 1,2,4,5-
tetraoxanes. While six alphaperoxides showed a high activity against NTS, only one was active against 
the adult worms. In a recent study using a random collection of 33 compounds with proven in vitro 
activity on adult schistosomes and 30 compounds with lacking adult activity, none of the compounds 
lacking activity on adult worms revealed significant activity on NTS.19 This finding suggests a superior 
susceptibility of schistosomula to peroxidic compounds. 
Since it was previously proposed that hemin increases the activity of peroxidic structures, as 
demonstrated for artemether25,26 additional experiments were conducted using hemin (Fe(III)) as well as 
heme (Fe(II)) in the incubation medium. Interestingly, only one tricyclic monoperoxide (compound 47) 
showed increased in vitro activity in the presence of hemin, likewise there was only one compound (29) 
which elucidated a slightly increased activity in the presence of heme. This moderately increased in vitro 
activity could be explained by an additional activation of the drug within the medium and not only within 
the parasites gut which was proposed as possible interaction site of hemin and artemether for S. 
japonicum.26 Most of the selected tetraoxanes showed similar to decreased efficacy when incubated 
with hemin or heme and no changes on the motility were observed in the supplemented media for the 
selected alphaperoxides. Note that slight fluctuations in IC50 values based on microscopical readout 
might be due to differences in sensitivities of worms or the subjective readout used. Nonetheless these 
results indicate that an antischistosomal activation of peroxides is not necessarily triggered by hemin or 
heme or at least does not represent the only activator since great variations were not observed for the 
two tested peroxide classes (alphaperoxides and 1,2,4,5- tetraoxanes) in the different media.  
Only low to moderate activity was observed for the two hit candidates, tetraoxane 18 (WBR: 43.1%) and 
the tricyclic monoperoxide 53 (WBR: 29.1%) against juvenile S. mansoni infections in mice which is in 
contrary to the recently investigated ozonides or the artemisinins.5,6 Hence, the activity profile of the 
investigated peroxides is different from previously studied peroxidic compounds, a finding which cannot 
be explained at the moment.  
Interestingly a high cytotoxic potential was observed for artesunate on all tested celllines, which is in 
accordance to recently shown induction of cell death by artemisinin compounds and cytotoxic 
observations on HepG2 cells.27 The activity of peroxides on blood-feeding parasites is most probably 
dependent on the activation of the endoperoxide bridge by an iron(II) species leading to C-centered 
radicals, which might be responsible for cytotoxicity.27-29 Hence, it is not surprising that some of the 
tested peroxides showed a higher cytotoxic potential on L6 -cells than the non peroxidic reference drug 
praziquantel. Furthermore it is known that the artemisinins possess cytotoxic potential on various cancer 
cell lines30 and apoptopic processes of fast proliferating cells in prescence of iron have been described.27 
It is worthwhile stating that the class of alphaperoxides did not show cyctotoxic potential at the highest 
concentration tested. Most of the tricyclic monoperoxides showed none to moderate cytotoxicity, 
whereas the class of tetraoxanes showed a similar cytotoxic potential as artesunate. With regard to our 
lead compounds (18 and 53) the conducted in vitro cytotoxicity assay on L6 - cells showed that both lead 
structures presented adequate selectivity indices when compared to artesunate. However compound 18 
elucidated an increased cytotoxic potential compared to artesunate on tested human cell-lines, which 
has to be kept in mind as potential drawback. 
In conclusion, the screening of three peroxides classes identified two interesting hit compounds, 
tetraoxane 18 and the tricyclic monoperoxide 53, which both revealed a high activity against adult S. 
mansoni in vivo. On the other hand, no promising activity was detected within the class of 
alphaperoxides. Our results hint to the fact that an adamantane group represents an important feature 
for antischistosomal activity. Compounds 18 and 53 might serve as starting candidates for further lead 
modifications aiming to increase activity on juvenile schistosomes and to lower cytotoxic potential.  
EXPERIMENTAL SECTION 
Drugs and media. The 63 (1-63) compounds belonging to three types of peroxide classes (bridged 
1,2,4,5-tetraoxanes, tricyclic monoperoxides and alphaperoxides) illustrated in Table 1 were prepared 
based upon methods described by Terent’ev and colleagues. 14-17 Additionally a 2-(1-adamantylperoxy)-
tetrahydrofuran (64), was prepared from 1-adamantylhydroperoxide and 2,3-dihydrofuran as described 
in the Supporting Information. 1-adamantylhydroperoxide was prepared from 1,3-dehydroadamantane 
and H2O2 in accordance with Son, V. V. and colleagues. 
31 A hemin solution (1.5 mM) was prepared as 
follows: 50 mg hemin-chloride (Fluka Analytical, Netherlands) was dissolved in 10 ml of 0.1M NaOH and 
39.5 ml of PBS (pH = 7.4). A Fe(II) heme solution (1.5 mM) was prepared by addition of 5 mM dithionite 
(Sigma Aldrich) to the prepared hemin solution, adapted from Barr et al. 32 Praziquantel and artesunate 
were purchased from Sigma-Aldrich GmbH.  
Synthesis and analytical data for key compounds. 7-(1-Adamantyl)-1,4-dimethyl-2,3,5,6-
tetraoxabicyclo[2.2.1]heptane 18.13 A 37% aqueous H2O2 solution (0.353 g, 3.84 mmol) was added to a 
solution of 3-(1-adamantyl)pentane-2,4-dione (0.3 g, 1.28 mmol) in EtOH (3 mL), the reaction mixture 
was cooled to 10°C, and a solution of H2SO4 (2 g, 0.02 mol) in EtOH (2 mL) was added with stirring. The 
reaction mixture was stirred at 20-25 °С for 1 h. Then CH2Cl2 (30 mL) was added. The organic layer was 
washed with water (2×10 mL), a 5% aqueous NaHCO3 solution (2×10 mL), and again with water (2×10 
mL), dried with Na2SO4, and filtered. The solvent was removed using a water-jet vacuum pump. Product 
7-(1-adamantyl)-1,4-dimethyl-2,3,5,6-tetraoxabicyclo[2.2.1]heptane 18 was isolated by silica gel 
chromatography with elution by a hexane – ethyl acetate (EA) mixture using the gradient of the latter 
from 0 to 30%. Product 18 was obtained in 68% yield (0.231 g, 0.87 mmol). White crystals. Mp = 130-131 
°C (partially decomposed). Rf = 0.60 (TLC, hexane: EA, 5:1). 
1Н NMR (300.13 MHz, CDCl3), : 1.63-2.04 (m, 
21H), 2.37 (s, 1H). 13С NMR (75.48 MHz, CDCl3), : 12.7, 28.3, 33.0, 36.7, 40.6, 66.8, 110.6. Anal. Calcd for 
C15H22O4: C, 67.64; H, 8.33. Found: 67.37; H, 8.61. 
3-(4-Methoxyphenyl)-6,7a-dimethyltetrahydro-3H,4H-3,6-epoxy[1,2]dioxolo[3,4-b]pyran 53.16 A 37% 
aqueous H2O2 solution (0.158 g, 1.72 mmol) and a solution of H2SO4 (1.0 g, 0.01 mol) in EtOH (1 mL) were 
added with stirring to a solution of 3-(4-methoxybenzoyl)heptane-2,6-dione (0.30 g, 1.14 mmol) in EtOH 
(4 mL) at 10−15 °C. The reaction mixture was stirred at 20−25 °C for 1 h, and a mixture of CH2Cl2: hexane 
= 1:1 (10 mL) was added. Then NaHCO3 was added to the reaction mixture with stirring until the pH 
reached 7.0. The precipitate was filtered off. The filtrate was dried over Na2SO4, the precipitate was 
filtered off, and the solvent was removed in a water jet vacuum. Product 3-(4-methoxyphenyl)-6,7a-
dimethyltetrahydro-3H,4H-3,6-epoxy[1,2]dioxolo[3,4-b]pyran 53 was isolated by chromatography on 
SiO2 using a hexane – ethyl acetate mixture as the eluent with a gradient of ethyl acetate from 5 to 50 
vol %. Product 53 was obtained in 41% yield (0.131 g, 0.47 mmol). White crystals. Mp = 89−90 °C. Rf = 
0.52 (TLC, hexane:EA, 2:1). 1H NMR (300.13 MHz, CDCl3): δ 1.55 (s, 3H), 1.61 (s, 3H), 1.68−1.80 (m, 4H), 
2.62−2.66 (m, H), 3.80 (s, 3H), 6.90 (d, 2H, J = 8.8 Hz), 7.49 (d, 2H, J = 8.8 Hz). 13C NMR (75.48 MHz, 
CDCl3): δ 12.5, 17.9, 24.8, 29.3, 50.5, 55.3, 95.8, 105.6, 106.5, 113.9, 124.7, 128.1, 160.5. Anal. Calcd for 
C15H18O5: C, 64.74; H, 6.52. Found: C, 64.73; H, 6.75. HRMS (ESI) m/z [M + H]
+ calcd for [C15H19O5]
+ 
279.1227; found 279.1227. 
Instrumentation and Methods. NMR spectra of novel compounds were recorded on a commercial 
instrument (300.13 MHz for 1Н, 75.48 MHz for 13С) in СDCl3. The TLC analysis was carried out on standard 
silica gel chromatography plates. The melting points were determined on a Kofler hot-stage apparatus. 
Chromatography was performed on silica gel (63-200 mesh). Elemental analysis on carbon, hydrogen, 
and nitrogen was carried out using a 2400 Perkin-Elmer CHN Analyzer. Determination of purity of all 
peroxides was executed by elemental (combustion) analysis. For all peroxides deviation from the 
theoretical values for C, H, and N content was less than 0.4%. These data confirm >95% purity of 
compounds 1-64. Structures of all compounds were confirmed using 1Н and 13С NMR spectra. 
Maintenance of mice and infection with S. mansoni. The in vivo studies were approved by the 
veterinary authorities of the Canton Basel-Stadt. Female NMRI mice (3-week old, weight ca. 14 g) were 
purchased from Charles River (Sulzfeld, Germany) or Harlan Laboratories (Horst, the Netherlands). Prior 
infection, animals were allowed to adapt for one week under controlled conditions (temperature ca. 22 
°C; humidity ca. 50 %; 12-hour light and 12-hour dark cycle; free access to rodent diet and water). Mice 
were infected with S. mansoni (Liberian strain) by subcutaneous injection of ~100 cercariae. Cercariae 
were harvested from infected intermediate host snails Biomphalaria glabrata by exposure to light for 3 
hours, following standard procedures of our laboratory.  
In vitro compound screening on S.mansoni NTS. Harvested S. mansoni cercariae were mechanically 
transformed to NTS following standard procedures. 33, 34 The obtained NTS suspension was adjusted to a 
concentration of 100 NTS per 50 µl using Medium 199 (Invitrogen, Carlsbad, CA) supplemented with 5% 
heat-inactivated fetal calf serum (iFCS), 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen, 
Carlsbad, CA). NTS suspensions were incubated (37°C, 5% CO2 in ambient air) for a minimum of 12 to 24 
h until usage to ensure completed conversion into schistosomula.35 On the following day drug dilution 
series were prepared in 96-flat bottom well-plates (BD Falcon, USA) with concentrations ranging from 
0.37 to 90 µg/ml (0.37, 1.1, 3.3, 10, 30, 90 µg/ml) using supplemented (iFCS and antibiotics) Medium 
199. The prepared NTS suspension was then added to each well and plates were incubated at 37°C, 5 % 
CO2. NTS incubated in the presence of the highest DMSO concentration served as control. NTS were 
evaluated by microscopical readout (Carl Zeiss, Germany, magnification 80x) with regard to death, 
changes in motility, viability, and morphological alterations 72 h post drug exposure. Drug effects were 
evaluated using a viability scale as described recently. 33, 34 Each concentration was tested in duplicate 
and experiments were performed at least three times. IC50 values of test compounds were determined as 
described before.36 Compounds were defined as highly active with IC50 values < 15 µM, moderate activity 
was defined as IC50 15-40 µM and low activity for values >40 µM.  
In vitro compound screening on adult S.mansoni. Highly active compounds (IC50 < 15 μM) on NTS were 
studied on adult schistosomes (workflow presented in Figure 1). Adult flukes were harvested from the 
hepatic portal veins and mesenteric veins of infected NMRI mice (7-8 weeks post infection) following 
standard procedures. 7 Schistosomes were placed in RPMI 1640 culture medium supplemented with 5% 
iFCS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C, 5% CO2 until usage. Supplemented RPMI 
1640 medium and drug stock solutions (10 mg/ml) were used to obtain final test concentrations of 1.1-
30 µg/ml (1.1, 3.3, 10, 30 µg/ml) in 24-flat bottom well-plates (BD Falcon, USA) with a final volume of 2 
ml. At least three schistosomes of both sexes were next added to each well. Schistosomes incubated in 
the presence of blank medium supplemented with the highest concentration of DMSO used in the assay 
served as control. Twenty-four, 48 and 72 h post drug exposure schistosomes were examined 
phenotypically using the motility scale described before 37 and an inverse microscope (Carl Zeiss, 
Germany, magnification 80x). Experiments were repeated at least three times and IC50 values 
determined.36 
The IC50 determination (72 h post drug exposure) for selected compounds was repeated with the 
addition of hemin (120 µM). Compounds showing high antischistosomal potential on the schistosomular 
stage (IC50 < 5 μM) but only moderate, low or no activity on adult schistosomes (without hemin 
supplementation) were selected for these additional experiments. Experiments were performed and 
repeated as described above with exception of hemin supplementation (120 µM) during the entire drug 
exposure time. Compounds which showed very good activities on NTS (IC50 < 5 μM) and lacked activity 
on adult worms were furthermore tested in Fe(II)-heme (120µM) supplemented media. 
Determination of cytotoxicity. The determination of cytotoxicity was performed with L-6 -cells according 
to a previously reported procedure. 38 Briefly, L-6 cells were seeded in 96-well microtiter plates at a 
density of 4*104 cells/ml in RPMI 1640 medium with 10 % fetal bovine serum and L-glutamine (2 mM). 
Drugs serially diluted three-fold ranging from 0.123 to 30 μg/ml in test medium were added. The plates 
were incubated at 37°C at an atmosphere of 5 % CO2. After 70 hours, Alamar Blue® (10 μL) was added to 
each well and incubation was continued for another 2 hours. The plate was then read using a 
SpectraMax M2 (MolecularDevices) instrument by use of an excitation wavelength of 530 nm and an 
emission wavelength of 590 nm. Fluorescence development was expressed as percentage of the control 
and the IC50 values were determined. Experiments were performed at least three times and IC50 values 
calculated as averages. The selectivity indices (SI) of tested compounds were calculated by dividing IC50 
obtained on L6- cells with IC50 values determined on adult S. mansoni.  
The cytotoxic potential of 2 lead candidates was additionally determined on human cervical carcinoma 
cells (HeLa) cells and human fetal Lung fibroblast cells (MRC-5) (see Supporting Information).  
In vivo testing. Compounds revealing an activity of < 15 μM on adult worms post 72 h drug exposure 
were tested in vivo. Groups of 4 infected NMRI mice characterized by a patent schistosome infection (49 
days post infection) were treated orally with the test drug using single oral doses of 400 mg compound 
per kg body weight. Eight to ten untreated mice served as controls. Fourteen days post-treatment 
animals were killed by the CO2 method, dissected and worms were sexed and counted. 
7 Worm burdens 
of treated mice were compared to untreated animals and reductions of worm burden calculated. 
Compounds displaying high activities against adult S. mansoni in vivo were also tested in the juvenile S. 
mansoni mouse model. For that purpose mice were treated with the test compounds 21-days post 
infection and killed so as dissected four weeks post treatment. Worm burden reductions were calculated 
as described above. 
Statistics. Parasite viability values of treated and untreated NTS and adult schistosomes obtained from 
sextuplicate evaluation were averaged (means (+/- standard deviation)) using Microsoft Excel software. 
IC50 values of test compounds were determined using the CompuSyn software (Version 3.0.1, 2007; 
ComboSyn, Inc). The Kruskal-Wallis test was applied for in vivo studies, comparing the medians of the 
worm burden reductions of the treatment and control groups. A difference in median was considered to 
be significant at a significance level of 5% (StatsDirect statistical software, version 2.7.2.; StatsDirect Ltd., 
United Kingdom).  
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Table 1 
Chemical structures of investigated structures presented regarding their peroxidic class. 
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In vitro activity of 3 different peroxide classes (alphaperoxides, bridged 1,2,4,5-tetraoxanes, and 
tricyclic monoperoxides) and one 2-(1-adamantylperoxy)-tetrahydrofuran on NTS and S. mansoni. R 
represents the “goodness of fit” whereas >0.85 is acceptable. 
Peroxide class Nr. IC50 NTS  r IC50 adult  r IC50 adult 
 hemin (120µM)  
r 
    S. mansoni  
[µM] 
  S. mansoni  
[µM]  
  S. mansoni  
[µM]  
 
Artesunate  4.97 0.9 41.2 0.8 38.7 0.7 
Praziquantel  2.2 0.9 0.1 0.9   
alphaperoxides 1 >104      
2 >795      
3 15.1 0.9     
4 26.5 0.9     
5 >111      
6 14.6 0.9 59.1 0.8   
7 9.0 0.9 >126.8    
8 37.8 0.8     
9 43.2 0.9     
10 67.7 1.0     
11 3.9 0.9 19.3 0.8 17.9 0.9 
12 5.0 0.9 14.7 0.9   
13 8.0 0.9 40.6 1.0   
14 10.7 0.9 122.9 0.9   
15 24.1 0.9     
16 157.0 0.9     




18 0.1 0.9 0.3 1.0   
19 0.2 1.0 61.5 0.9 27.3 0.9 
20 0.4 0.9 35.5 0.9 25.3 1.0 
21 0.5 1.0 37.8 1.0 >159  
22 0.6 0.9 30.9 1.0 41.2 0.9 
23 0.8 0.8 33.3 1.0 39.3 1.0 
24 1.0 0.9 33.6 0.9 47.7 0.9 
25 1.1 0.9 18.8 1.0 12.9 0.9 
26 1.2 0.8 40.0 0.9 >127  
27 1.2 0.8 132.4 0.9 91.9 0.9 
28 3.4 0.9 49.8 0.9 >174  
29 3.4 0.9 >89.8  >89.8  
30 4.4 1.0 >112  >112  
31 5.0 0.9 41.4 0.7 134.9 0.9 
32 5.5 0.9 50.1 0.9   
33 6.1 1.0 65.6 0.9   
34 6.6 1.0 >110.6    
35 7.1 0.8 35.5 1.0   
36 8.9 0.9 66.6 0.9   
37 9.8 0.9 >129.2    
38 10.7 0.9 36.9 0.8   
39 10.9 0.9 >102    
40 11.7 0.9 >103.7    
41 13.9 0.9 >117    
42 15.3 1.0     
43 25.6 0.9     




45 1.7 0.8 8.7 0.9   
46 3.5 0.9 >105  92.2 0.9 
47 4.5 0.9 >103  13.4 0.9 
48 8.1 1.0 82.4 0.9   
49 9.0 0.9 12.2 0.8   
50 9.0 1.0 19.2 0.9   
51 9.3 0.8 7.7 0.9   
52 13.4 0.9 >109    
53 14.4 0.8 11.7 0.9   
54 15.6 0.9     
55 16.0 0.9     
56 22.3 0.9     
57 22.5 0.8     
58 45.3 0.9     
59 180.4 0.9     
60 213.2 0.9     
61 >287      
62 >348      




64 >125.9      
*as described by Keiser et al . J Antimicrob Chemother 2011; 66: 1791– 1797 
 
Table 3 
IC50 values of eight selected hit compounds (12, 18, 25, 45, 47, 49, 51 and 53) evaluated with L6-cells 
and adult S. mansoni worms. Selectivity Indices (SI) were calculated based on evaluated IC50 values 
and Artesunate so as Praziquantel served as control compounds. 
Compound IC50 [µM] SI 
L6- cells (SD) S. mansoni 
12 99.0 (11.0) 14.7 6.4 
18 1.7 (0.3) 0.3 5.7 
25 2.2 (0.4) 18.8 0.1 
45 8.2 (1.9) 8.7 0.9 
47 > 103 13.4 > 7.7 
49 > 93 12.2 > 7.6 
51 10.3 (1.8) 7.7 1.3 
53 58.3 (17.9) 11.8 4.9 
Artesunate 1.5 (0.6) 38.7 0.04 
Praziquantel > 96 0,1 > 960 
 
SD: Standard deviation; SI: Selectivity Index 
 
Table 4  
In vivo activity of selected compounds from 3 different peroxide classes (bridged 1,2,4,5-tetraoxanes, 
tricyclic monoperoxides, alphaperoxides). All tested on patent adult schistosoma infection (49 days 
post treatment) and promising candidates as well on juvenile schistosoma infections (21 days post-
treatment) 














TWR FWBR  TWR  FWBR  
controla 9 29 (28.5) 13.3 (12.9) - - - - 
controlb 8 38.3 (18.1) 20.6 (8.8) - - - - 
controlc 10 30.6 (24.7) 16.1 (13) - - - - 
controld 8 21.6 (12.2) 11.0 (6.4) - - - - 
12a  4 32.3 (21.4) 17.3 (11.6) 0.0 0.0   
18a  6 6.7 (2.5) 2.3 (1.2) *75.4 *77.8 43.1 50 
25d 2 20.5 (11.5) 10.5 (9.2) 5.0 4.6   
45c 4 21 (2.2) 10.3 (3.1) 31.3 36.4   
47d 4 22.3 (4.9) 12 (2.4) 0.0 0.0   
49d 4 23.5 (5.9) 11.8 (3.1) 4.7 9.6   
51b 4 35.8 (8.2) 17.5 (6.6) 6.5 15.2   
53c 4 5.3 (5) 2.8 (2.6) *82.8 *82.9 18.9 27.3 
TWR: Total worm burden reduction; FWBR: Female worm burden reduction; SD: Standard deviation;  










List of nonstandard abbreviations and acronyms 
NTS, newly transformed schistosomula; WBR, worm burden reduction; TWBR, total worm burden 
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